ANTHERA PHARMACEUTICALS INC
ANTHERA PHARMACEUTICALS INC (ANTH): 3 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.6 months
D/E 0.61 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for ANTHERA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$26K
Cash
$8.1M
Quarterly Burn
$9.4M
Runway
2.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| blisibimod | Phase 2 |
| lidocaine | Approved |
| sollpura | Phase 3 |
Frequently asked questions
How many drug candidates are in ANTHERA PHARMACEUTICALS INC's pipeline?
ANTHERA PHARMACEUTICALS INC (ANTH) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ANTHERA PHARMACEUTICALS INC's lead drug candidate?
ANTHERA PHARMACEUTICALS INC's most advanced tracked candidate is blisibimod (Phase 2) for Immunoglobulin A nephropathy (IgA nephropathy).
What is ANTHERA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ANTHERA PHARMACEUTICALS INC has approximately 2.6 months of cash runway.
What is ANTHERA PHARMACEUTICALS INC's market capitalization?
ANTHERA PHARMACEUTICALS INC's market capitalization is approximately $26K.
Who is the CEO of ANTHERA PHARMACEUTICALS INC?
Craig Thompson is the chief executive officer of ANTHERA PHARMACEUTICALS INC (ANTH).
Get the full picture on ANTHERA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.